15 patents
Utility
Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3)
28 Dec 23
Provided herein are anti-T Cell Immunoglobulin and Mucin Protein-3 (TIM-3) antibodies having particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences and methods of using the anti-TIM-3 antibodies to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.
David J. King, Marilyn Kehry, Srimoyee Ghosh, Baochuan Huang
Filed: 18 Jul 23
Utility
B and T Lymphocyte Attenuator (Btla) Modulators and Method of Using Same
7 Dec 23
A BTLA-binding agent and immunoglobulin heavy chain and light chain polypeptides of the binding agent, as well as methods of using the BTLA-binding agent to treat a disorder or disease that is responsive to BTLA agonism, such as an autoimmune or inflammatory disease.
Martin Edward Dahl, Stephen Parmley, Marilyn Kehry, Jean da Silva Correia, Morena Shaw
Filed: 22 Oct 21
Utility
Antibodies Directed Against Programmed Death-1(PD-1)
19 Oct 23
The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a programmed death-1 (PD-1) protein.
David J. King, Marilyn Kehry
Filed: 14 Jun 23
Utility
Anti-interleukin 36 Receptor (IL-36R) Therapy for Ichthyosis
31 Aug 23
The invention relates to methods of treating ichthyosis in a subject with an inhibitor of the interleukin 36 (IL-36) pathway, and methods of selecting a subject for therapy with the IL-36 pathway inhibitor.
Amy Paller, Emma Guttman, Irina Khanskaya, Rupal Kalapanda, Marco Londei
Filed: 30 Jul 21
Utility
PD-1 Agonist and Method of Using Same
28 Jul 22
Provided is a PD-1-binding agent comprising an immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide, as well as related compositions and methods for making and using same.
Marilyn KEHRY, Stephen PARMLEY, Robert P. MORSE, Gregory N. GOLD, Janean FISHER, Martin Edward DAHL, Margaret Habash MARINO, Rupal KALAPANDA
Filed: 4 Jun 20
Utility
Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3)
2 Jun 22
The disclosure provides antibody agents that bind to a T Cell Immunoglobulin and Mucin Protein-3 (TIM-3) protein.
David J. King, Marilyn Kehry, Srimoyee Ghosh, Baochuan Huang
Filed: 27 Oct 21
Utility
Antibody Agents Directed Against Lymphocyte Activation GENE-3 (LAG-3) and Uses Thereof
5 May 22
The disclosure provides antibody agents that bind to a Lymphocyte Activation Gene-3 (LAG-3) protein.
Helen Toni Jun, Marilyn Kehry, Peter Bowers, David J. King, Dmitri Bobilev, Srimoyee Ghosh, Baochuan Huang, David Jenkins
Filed: 27 Apr 18
Utility
Antibodies Directed Against Programmed Death-1 (PD-1)
24 Mar 22
The disclosure provides antibody agents that bind to a programmed death-1 (PD-1) protein.
David J. King, Marilyn Kehry, Baochuan Huang
Filed: 27 Sep 21
Utility
Antibodies Directed Against Interleukin 36 Receptor (IL-36R)
16 Dec 21
The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R).
Peter BOWERS, Andrew John MCKNIGHT, David J. KING, Marco LONDEI
Filed: 26 Aug 21
Utility
Antibodies Directed Against Programmed Death-1(PD-1)
3 Jun 21
The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a programmed death-1 (PD-1) protein.
David J. King, Marilyn Kehry
Filed: 13 Jul 20
Utility
Antibodies Directed Against Lymphocyte Activation Gene 3 (LAG-3)
1 Apr 21
The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the Lymphocyte Activation Gene-3 (LAG-3).
Helen Toni Jun, Marilyn Kehry, Peter Bowers, David J. King
Filed: 19 Oct 20
Utility
Antibodies Directed Against INTERLEUKIN-33 (IL-33)
11 Feb 21
The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33).
Robert A. Horlick, David J. King, Andrew John McKnight
Filed: 15 Oct 20
Utility
ANTI-IL-33 Therapy for Atopic Dermatitis
29 Jul 20
Methods of treating atopic dermatitis in a patient with an anti-IL-33 antibody, and methods of selecting atopic dermatitis patients for anti-IL-33 therapy.
Marco LONDEI
Filed: 8 Oct 18
Utility
Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3)
13 May 20
The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the T Cell Immunoglobulin and Mucin Protein-3 (TIM-3).
Marilyn KEHRY, David J. KING, Jean DA SILVA CORREIA
Filed: 16 Oct 19
Utility
Antibodies Directed Against Interleukin 36 Receptor (IL-36R)
18 Mar 20
The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R).
Peter BOWERS, Andrew John MCKNIGHT, David J. KING, Marco LONDEI
Filed: 17 Nov 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first